At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 35 enrolled
Drug / intervention
LMN-301biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Single-site, Open-label Study to Determine the Safety and Tolerability of Single and Multiple Doses of Intranasally Administered LMN-301 in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating LMN-301 for COVID-19. Completed, enrolled 35 participants across 1 site.
Detailed Summary
LMN-301 is to prevent infection by severe acute respiratory syndrome-corona virus (SARS-CoV-2) (the virus causing coronavirus disease of 2019 (COVID-19) in uninfected individuals. This study aims to assess whether the formulation will cause irritation when administered in the nose, and how long its protective effects will last. Thirty five healthy adult volunteers will participate in this study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesAustralia
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
First PostedSep 2023
Enrollment StartOct 2023
Primary CompletionDec 2023
Study CompletionApr 2024
TodayJul 2026
First PostedSep 11, 2023
Enrollment StartOct 6, 2023
Primary CompletionDec 28, 2023
Study CompletionApr 3, 2024
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 2.8 years ago
Interventions
LMN-301biological
Intranasally administered powder.